Meeting
2020 ASCO Virtual Scientific Program
Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma.
Authors
Payal D Shah
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA
Payal D Shah , Alexander Chan Chi Huang , Xiaowei Xu , Paul J. Zhang , Robert Orlowski , Tina Matlawski , Joanne Shea , Amanda Cervini , Ravi K. Amaravadi , Julia C. Tchou , Lynn Mara Schuchter , E. John Wherry , Gerald P. Linette , Rosemarie Mick , Irina Kulikovskaya , Simon F. Lacey , Gabriela Plesa , Carl H. June , Robert H. Vonderheide , Tara C. Mitchell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03060356
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10035)
DOI
10.1200/JCO.2020.38.15_suppl.10035
Abstract #
10035
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2024 ASCO Genitourinary Cancers Symposium
Alterations in tumor immune microenvironment and progressive immune exhaustion with advancing penile squamous cell carcinoma using multiplex immunofluorescence and image analysis.
First Author: Keerthi Gullapalli
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe